LONDON — Britain’s public spending watchdog is probing the cost of Donald Trump’s drug pricing deal with the U.K., after six committee chairs called for an investigation. “I recognize that there is significant parliamentary interest in the arrangement, and I have therefore instructed my team to make preliminary enquiries about this matter,” the head of the National Audit Office (NAO), Gareth Davies, said in his response to lawmakers’ concerns. The six committee chairs sent a letter to the NAO last month , urging the spending watchdog to investigate how much the U.K.-U.S. drug pricing deal will cost taxpayers and whether it offers value for money. The deal saw the U.K. commit to doubling its spending on innovative medicines by 2035 from 0.3% to 0.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.